Diane Young compensation by year
Celldex Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Salary | $430,163 | $445,219 | $461,848 |
| Bonus | $200,000 | $192,274 | $228,000 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $1,564,970 | $1,295,724 | $2,269,752 |
| Non-equity incentive | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $5,834 | $6,004 | $6,605 |
| Total | $2,200,967 | $1,939,221 | $2,966,205 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Celldex Therapeutics, Inc. DEF 14A filed April 25, 2024, accession 0001104659-24-051634, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Celldex Therapeutics, Inc. filed document, accession 0001104659-24-051634. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 80,000 | — | $36.87 |
| Option | 47,500 | — | $22.48 |
| Option | 27,000 | — | $28.00 |
| Option | 9,000 | — | $10.38 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Celldex Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
6 Form 4 lines since the FY2023 proxy (filed April 25, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-25 | Grant or award derivative | — | 57,000 | $0.00 | 57,000 |
| 2025-06-05 | Grant or award derivative | — | 72,000 | $0.00 | 72,000 |
| 2024-06-13 | Grant or award derivative | — | 72,000 | $0.00 | 72,000 |
| 2024-06-11 | Exercise or conversion | — | 15,000 | $2.71 | 17,115 |
| 2024-06-11 | Exercise or conversion derivative | — | 15,000 | $0.00 | 0 |
| 2024-06-07 | Sale | — | 45,000 | $35.26 | 2,115 |
The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Celldex Therapeutics’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Anthony Marucci | President and Chief Executive Officer | $8,361,844 |
| Tibor Keler | Executive Vice President and Chief Scientific Officer | $3,420,609 |
| Diane Young · this page | Senior Vice President, Chief Medical Officer | $2,966,205 |
| Sam Martin | Senior Vice President and Chief Financial Officer | $2,946,626 |
| Margo Heath-Chiozzi | Senior Vice President, Regulatory Affairs | $2,936,966 |
Board service
Celldex Therapeutics board · FY2023How this board is paid
Company policy: Celldex Therapeutics pays directors a $43,200 cash retainer. As stated in Celldex Therapeutics's FY2023 proxy.
The full Celldex Therapeutics compensation record
free company briefThis page is one person within Celldex Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Celldex Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Celldex Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.